Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 4/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 3/20 | 1.00 |
| ▸ | RELA | Q04206 | 3/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 2/20 | 1.00 |
| ▸ | HSD17B2 | P37059 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | SRC | P12931 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.79 |
| ▸ | MAPT | P10636 | 4/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.79 |
| ▸ | HPGD | P15428 | 3/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butein SCHEMBL29724857 | 1.00 | KMT2A (1.00) | KMT2AMEN1NFKB1NFKB2RELA | |
| Butein SCHEMBL243647 | 1.00 | KMT2A (1.00) | KMT2AMEN1NFKB1NFKB2RELA | |
| Butein SCHEMBL30383523 | 1.00 | KMT2A (1.00) | KMT2AMEN1NFKB1NFKB2RELA | |
| Butein SCHEMBL243646 | 1.00 | KMT2A (1.00) | KMT2AMEN1NFKB1NFKB2RELA | |
| Butein SCHEMBL139243 | 1.00 | KMT2A (1.00) | KMT2AMEN1NFKB1NFKB2RELA | |
| Butein SCHEMBL25202104 | 1.00 | KMT2A (1.00) | KMT2AMEN1NFKB1NFKB2RELA | |
| Butein SCHEMBL25200377 | 0.98 | KMT2A (0.97) | KMT2AMEN1NFKB1NFKB2RELA | |
| SCHEMBL25208375 | 0.90 | MEN1 (0.96) | KMT2AMEN1NFKB1NFKB2RELA | |
| Butein SCHEMBL25209583 | 0.89 | KMT2A (0.80) | KMT2AMEN1NFKB1NFKB2RELA | |
| Butein SCHEMBL1706409 | 0.89 | KMT2A (0.80) | KMT2AMEN1NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114642695-A | Big data traditional Chinese medicine composition for regulating and controlling prostate cancer | 华子昂 | 2022-06-21 | — | — | CN | claimed |
| US-10588854-B2 | Polymer implants for treatment of metabolic disorders | UNIVERSITY OF SOUTH CAROLINA (US) | 2020-03-17 | — | — | US | claimed |
| US-20190000749-A1 | Polymer Implants for Treatment of Metabolic Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-01-03 | — | — | US | claimed |
| US-9828407-B2 | Water soluble and activable phenolic derivatives with dermocosmetic and therapeutic applications and process for preparing said derivatives | LIBRAGEN (FR) | 2017-11-28 | — | — | US | claimed |
| US-20140088030-A1 | WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES | LIBRAGEN (FR) | 2014-03-27 | — | — | US | claimed |
| EP-1888174-B1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | JOHNSON & JOHNSON CONSUMER (US) | 2012-02-22 | — | — | EP | claimed |
| US-20100056482-A1 | Calixarene Derivatives as Anticancer Agent | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2010-03-04 | — | — | US | claimed |
| EP-1888174-A1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | Johnson and Johnson Consumer Companies, Inc. (US) | 2008-02-20 | — | — | EP | claimed |
| WO-2006127539-A1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2006-11-30 | — | — | WO | claimed |
| US-20060270614-A1 | Use of chalcones for the treatment of viral disorders | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2006-11-30 | — | — | US | claimed |
| WO-2005004814-A2 | SIRT1 AND GENETIC DISORDERS | ELIXIR PHARMACEUTICALS, INC. (US) | 2005-01-20 | — | — | WO | claimed |
| WO-1995006628-A1 | TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES OR BACTERIA | STATENS SERUMINSTITUT (DK) | 1995-03-09 | — | — | WO | claimed |
| EP-0399051-B1 | POLYVALENT ANTIINFLAMMATORY AGENT | DAINIPPON INK & CHEMICALS (JP) | 1994-05-11 | — | — | EP | claimed |
| US-5234951-A | Anti-ulcer agent comprising chalcone derivative | TSUMURA JUNTENDO, INC. (JP) | 1993-08-10 | — | — | US | claimed |
| US-5109025-A | Use of 2',3,4,4'-tetrahydroxychalcone (butein) | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1992-04-28 | — | — | US | claimed |
| EP-0399051-A1 | POLYVALENT ANTIINFLAMMATORY AGENT | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1990-11-28 | — | — | EP | claimed |
| EP-0292576-A1 | ANTI-ULCEROUS AGENT CONTAINING CHALCONE DERIVATIVE AS EFFECTIVE INGREDIENT AND NOVEL CHALCONE DERIVATIVES | TSUMURA & CO. (JP) | 1988-11-30 | — | — | EP | claimed |
| JP-63010720-A | — | — | None | — | — | JP | disclosed |
| EP-0292576-A1 | ANTI-ULCEROUS AGENT CONTAINING CHALCONE DERIVATIVE AS EFFECTIVE INGREDIENT AND NOVEL CHALCONE DERIVATIVES | TSUMURA & CO. (JP) | 1988-11-30 | — | — | EP | disclosed |
| JP-S6310720-A | 5-LIPOXYGENASE INHIBITOR AND ANTI-ALLERGIC AGENT | NIPPON KAYAKU CO LTD | 1988-01-18 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10588854-B2 | Polymer implants for treatment of metabolic disorders | LRBA, FABP4, APMAP | KMT2A 1073/4885MEN1 3428/4885NFKB1 1970/4885 |
| US-20060270614-A1 | Use of chalcones for the treatment of viral disorders | HAVCR2, HMGB3, EIF2AK2 | KMT2A 4014/4885MEN1 3326/4885NFKB1 1144/4885 |
| US-20140088030-A1 | WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES | UGGT1, TYR, G6PD | KMT2A 1919/4885MEN1 4300/4885NFKB1 832/4885 |
| US-20100056482-A1 | Calixarene Derivatives as Anticancer Agent | CALU, CALR, CALD1 | KMT2A 4793/4885MEN1 4432/4885NFKB1 1305/4885 |
| US-20190000749-A1 | Polymer Implants for Treatment of Metabolic Disorders | LRBA, FABP4, APMAP | KMT2A 1073/4885MEN1 3428/4885NFKB1 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.